1. Home
  2. BZUN vs CHRS Comparison

BZUN vs CHRS Comparison

Compare BZUN & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Baozun Inc.

BZUN

Baozun Inc.

HOLD

Current Price

$2.94

Market Cap

164.5M

ML Signal

HOLD

Logo Coherus BioSciences Inc.

CHRS

Coherus BioSciences Inc.

HOLD

Current Price

$1.37

Market Cap

177.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BZUN
CHRS
Founded
2007
2010
Country
China
United States
Employees
N/A
N/A
Industry
Catalog/Specialty Distribution
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
164.5M
177.7M
IPO Year
2014
2014

Fundamental Metrics

Financial Performance
Metric
BZUN
CHRS
Price
$2.94
$1.37
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$5.51
AVG Volume (30 Days)
166.8K
868.0K
Earning Date
05-20-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
472.00
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$7.89
$73.08
Revenue Next Year
$6.16
$30.94
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.07
$1.09
52 Week High
$4.31
$2.62

Technical Indicators

Market Signals
Indicator
BZUN
CHRS
Relative Strength Index (RSI) 58.88 54.27
Support Level $2.71 $1.33
Resistance Level $2.98 $1.51
Average True Range (ATR) 0.09 0.08
MACD 0.01 -0.00
Stochastic Oscillator 97.92 92.16

Price Performance

Historical Comparison
BZUN
CHRS

About BZUN Baozun Inc.

Baozun Inc is engaged to provide its customers with end-to-end e-commerce solutions including the sales of apparel, home and electronic products, online store design and setup, visual merchandising and marketing, online store operations, customer services, warehousing and order fulfillment, as well as the holistic brand management, including tactic positioning, branding and marketing, retail and e-commerce operations, supply chain and logistics, and technology empowerment. It has two operating segments: E-Commerce (encompassing BEC and BZI) and Brand Management (representing BBM). The company generates maximum of its revenue from E-Commerce (encompassing BEC and BZI) segment.

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.

Share on Social Networks: